Michael Stevens
Member, Board of Directors
Michael Stevens is currently a Director of Oxford-Emergent Tuberculosis
Consortium (OETC) Limited, a UK based joint venture between the
University of Oxford and Emergent Biosolutions Inc to develop the
world’s most clinically advanced tuberculosis vaccine – MVA85A, and a
member of the Advisory Board of Chiesi Farmaceutici SpA, a private
Italian international pharmaceutical group. In addition, he is a
business advisor to the Chief Executive Officer of Gedeon Richter Ltd.,
Hungary. Until his retirement in July 2005, Mr. Stevens was Executive
Vice President at GE Healthcare and previously was Corporate Development
Director of Amersham Plc. During his career he held senior positions at
major pharmaceutical companies, notably Gedeon Richter Ltd., Wellcome
Plc, and Syntex Corporation in California. Mr. Stevens is a Fellow of
the Chartered Institute of Management Accountants and has studied at
INSEAD business school in France.
Share This Page:
![[ Skip Navigation ]](../../images/c.gif)
